Stelara Leads to High Clinical Response, Remission in Severely Active Crohn’s, Phase 3 Study Shows
News
Almost 80% of patients with severely active Crohn’s disease (CD) responded to treatment with Stelara (ustekinumab) and two-thirds achieved clinical remission, according to 16-week results from a Phase 3 clinical trial. ... Read more